COPD Case Finding In Nottingham and District: C-FIND COPD A Pilot Study (C-FIND)

December 12, 2025 updated by: Nottingham University Hospitals NHS Trust

The Targeted Lung Health Check (TLHC) is currently being rolled out in many regions of the United Kingdom and has just started in Nottingham. The same cohort of people are also at high risk for Chronic Obstructive Pulmonary Disease (COPD), a lung condition often caused by smoking and leading to breathlessness and cough. This study aims to provide pilot evidence of the role of breathing tests in those who have had a Computerised Tomography (CT) scan, in order to early diagnose COPD. Currently, at diagnosis, many patients have lost 30-40% of lung function already, which is not reversible.

This study will use the Nottingham University Hospitals Trust Mobile Research Unit. The unit will follow the CT scanner route 2-3 weeks later, and people who have had a CT scan will be invited for breathing tests. Participants will also collect further information on potential treatment options for people diagnosed with COPD earlier -including smoking cessation, symptom management and general health advice (vaccinations, diet, activity and managing infections). There is also an optional blood test.

The study aims are to determine the uptake and acceptability of breathing tests in patients at high risk of COPD, and if a community based approach co-locating with TLHC can increase uptake.

A qualitative sub-study has been added to assess the opportunities or barriers for people being invited for a COPD diagnosis visit in the community. This sub-study will have a recruitment target of 20 participants. It will involve transcribed interviews. This will help determine the accessibility of the mobile research unit in use for this study.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

Ever smokers, aged between 55 to 74 years are invited for a telephone risk assessment. Those who are high risk (based on validated lung cancer risk scores, which incorporate a number of variables, including age and smoking intensity) are then sequentially invited for a CT scan in a certain locality of Nottingham as part of the TLHC. As the programme is introduced the number of invites per month will increase from 500 to 1800. It is anticipated that 40 to 45% of those will take up the invite and have a CT scan. At the time of their CT scan all smokers will be offered smoking cessation.

The clinical pathway incorporates that the CT scans will be reported by Heart Lung Health , with responsible clinician - Dr O'Dowd. Patients identified as having cancer or high likelihood will be approached and commenced on a cancer diagnostic pathway. This study addresses people who are not entering this pathway.

Two-three weeks after the CT scan, the clinical team will invite people to attend for a research study to assess lung health if they have symptoms of cough, breathlessness or 2 or more courses antibiotics in the last 15 months. No further reminder will be sent. The investigators will not excluding people with COPD already and will not turn away high-risk people who self-present even if not had a CT.

The invite will include mention of when the mobile unit is open and in their locality, what the visit consists of and that participants are free to come down at a convenient time. A telephone number and e-mail will be provided if somebody contacts the investigators and would prefer to be seen in a standard research unit - an appointment will be provided. The letter will remind participants that this cannot cover broader medical issues or emergencies, where usual clinical advice should be sought.

Following informed consent, the following will occur by trained clinical research practitioners and under the support of a research nurse.

  • Questionnaires:

    • Symptom scores and information on tobacco smoking / other exposures, past medical history, medication
    • COPD Assessment Test (CAT) Quality of Life score
    • Medical Research Council (MRC) breathlessness score
    • Exacerbation frequency
    • EQ5D - Health Status
  • Observations:

    • Oximetry for heart rate and oxygen saturations
    • Height
    • Weight
    • Blood pressure
  • Postbronchodilator spirometry - salbutamol delivered by trained staff.
  • Forced Oscillation Technique (FOT)- a non-clinically used breathing test but might have a role in early detection.
  • Approach for future research and store research data obtained here / review medical records for future medicines.
  • Invite to provide a blood sample and nasal swab for early markers of COPD - optional and currently of no clinical relevance.

Those with clinical evidence of COPD will be given information by a registered Health Care professional trained to do so on:

  • COPD and what it is.
  • Need for immunisations.
  • General health education, self-management and tobacco cessation where indicated.
  • Whether further review at the surgery is required.
  • Clinical information will be fed back to primary care surgery and uploaded onto medical health records, such as SystemOne. The participant will have consented to this.

The investigators will seek feedback from participants and subsequently from the primary care clinicians.

A qualitative sub-study has been added to assess the opportunities or barriers for people being invited for a COPD diagnosis visit in the community. This sub-study will have a recruitment target of 20 participants. It will involve transcribed interviews. This will help determine the accessibility of the mobile research unit in use for this study.

Study Type

Observational

Enrollment (Actual)

568

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Nottinghamshire
      • Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
        • Nottingham University Hospitals Nhs Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

The Targeted Lung Health Check (THLC) cohort are a population that are at high risk for COPD, a lung condition often caused by smoking. This same population will be invited to undertake breathing test in order to early diagnose COPD.

Description

Inclusion Criteria:

  • Smoking history - either compatible with TLHC (current or ex-smoker who are high risk based on lung cancer risk scores) or if self-presenting >10 pack years (current or ex)
  • Able to provide full informed consent.

Exclusion Criteria:

  • People currently undergoing active investigation or treatment for cancer
  • Unable to provide informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of people who take up the invite to attend for a C-FIND visit.
Time Frame: 1.5 years
0-100%
1.5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion diagnosed with COPD
Time Frame: 1.5 years
0-100%
1.5 years
Exacerbation Frequency
Time Frame: 1 day
0-12/year
1 day
Oximetry for oxygen saturations
Time Frame: 1 day
75-100% Oxygen saturation
1 day
Height
Time Frame: 1 day
Participant height in metres - range 1.2-2.0m
1 day
Weight
Time Frame: 1 day
participant weight in Kg - range 35-180Kg
1 day
BMI
Time Frame: 1 day
12-60g/m2
1 day
Blood pressure diastolic
Time Frame: 1 day
40-120mmHg
1 day
Post bronchodilator Spirometry
Time Frame: 1 day
Forced Expired Volume (FEV)% - range 10-140% predicted
1 day
FOT-R (Resistance)
Time Frame: 1 day
cmH2O.s/l
1 day
FOT-X (reactance)
Time Frame: 1 day
cmH2O.s/l
1 day
FOT-AX (area of reactance)
Time Frame: 1 day
cmH2O/L
1 day
FOT-Fres (resonant Frequency)
Time Frame: 1 day
Hz
1 day
Blood pressure -systolic
Time Frame: 1 day
75-230mmHg
1 day
CAT COPD Quality of Life Score
Time Frame: 1 day
Questionnaire. Wellbeing and daily life questions, scored 0-40 points, lower better
1 day
MRC breathlessness score
Time Frame: 1 day
Questionnaire, self reported breathlessness grade 1-5, lower better
1 day
EQ-5D-5L - Health Status
Time Frame: 1 day
Questionnaire. Self reported health scale 0-100. Greater better
1 day
What are the opportunities or barriers for people being invited for a COPD diagnosis visit in the community
Time Frame: From enrolment to the end of study
To assess the barriers and opportunities presented by the use of the mobile research unit
From enrolment to the end of study

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Charlotte Bolton, MD, PhD, Nottingham University Hospitals Nhs Trust

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 21, 2023

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

July 20, 2023

First Submitted That Met QC Criteria

August 15, 2023

First Posted (Actual)

August 23, 2023

Study Record Updates

Last Update Posted (Actual)

December 19, 2025

Last Update Submitted That Met QC Criteria

December 12, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 23RM005

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Search Similar Trials